Efficacy and safety of a putative anxiolytic agent: ipsapirone.

Abstract

Ipsapirone is an azopirone derivative that selectively interacts with serotonin-1A (5-HT1A) receptors and fails to affect other neurotransmitter receptors. In this study, ipsapirone at 15 mg or 30 mg was compared with diazepam at 15 mg and placebo in a double-blind, random assignment study design in patients with generalized anxiety disorder (GAD). During 4 weeks of treatment, both active drugs were therapeutically superior to placebo, without significant drug vs. drug therapeutic differences. The side-effect profile of ipsapirone at 15 mg was favorable compared to diazepam, but at 30 mg ipsapirone produced significant gastrointestinal disturbances.

• Authors: R L Borison, J W Albrecht, B I Diamond
• Journal: Psychopharmacology bulletin (Psychopharmacol Bull) Vol. 26 Issue 2 Pg. 207-10 ( 1990) ISSN: 0048-5764 [Print] United States
• PMID: 1978371 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Anti-Anxiety Agents
• Pyrimidines
• ipsapirone
• Diazepam

Topics

• Adult
• Anti-Anxiety Agents (adverse effects, therapeutic use)
• Anxiety Disorders (drug therapy, psychology)
• Diazepam (adverse effects, therapeutic use)
• Double-Blind Method
• Female
• Humans
• Male
• Middle Aged
• Psychiatric Status Rating Scales
• Pyrimidines (adverse effects, therapeutic use)